Cure Today

FDA Grants Capivasertib Plus Faslodex Priority Review for Breast Cancer

The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has ...
Cure Today

Truqap Plus Faslodex Boosts Breast Cancer Outcomes, Quality of Life

Patients with HR-positive, HER2-negative breast cancer tended to have longer health-related quality of life and improved outcomes with Truqap plus Faslodex, research showed. Health-related quality of ...
markets.financialcontent

Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

Positive high-level results from the CAPItello-291 Phase III trial showed that AstraZeneca’s capivasertib in combination with FASLODEX® (fulvestrant) demonstrated a statistically significant and ...
streetinsider

Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with FASLODEX® (fulvestrant) has been accepted and granted Priority Review in the US for ...
streetinsider

AstraZeneca (AZN) announces Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

AstraZeneca's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...